Menopausal Hormone Therapy

Current Considerations

      Keywords

      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Endocrinology and Metabolism Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Isaacs D.
        • Fitzgerald D.
        Seven alternatives to evidence-based medicine.
        Oncologist. 2001; 6: 390-391
        • Wilson R.A.
        Feminine forever.
        M. Evans and Co., Inc; J.B. Lippincott Co, New York; Philadelphia1966
        • Huss K.S.
        Estrogen therapy (The book forum).
        JAMA. 1966; 197: 196
        • Santen R.J.
        • Allred D.C.
        • Ardoin S.P.
        • et al.
        Postmenopausal hormone therapy. An endocrine society scientific statement.
        J Clin Endocrinol Metab. 2010; 95: S1-S66
        • Grady D.
        • Rubin S.M.
        • Petitti D.B.
        • et al.
        Hormone therapy to prevent disease and prolong life in postmenopausal women.
        Ann Intern Med. 1992; 117: 1016-1037
      1. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
        JAMA. 1995; 273: 199-208
        • Rossouw J.E.
        • Anderson G.L.
        • Writing Group for the Women’s Health Initiative
        • et al.
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women.
        JAMA. 2002; 288: 321-333
        • Anderson G.L.
        • Limacher M.
        • The Women’s Health Initiative Steering Committee
        • et al.
        Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial.
        JAMA. 2004; 291: 1701-1712
        • Harman S.M.
        • Black D.M.
        • Naftolin F.
        • et al.
        Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women.
        Ann Intern Med. 2014; 161: 249-260
      2. Hodis HN, Mack WJ, Shoupe D, et al. Testing the menopausal hormone therapy timing hypothesis: the Early versus Late Intervention Trial with Estradiol. American Heart Association Annual Meeting. Abstract Oral Session, Number 13283. Chicago, Illinois, November 18, 2014.

        • Tsai S.A.
        • Stefanick M.L.
        • Stafford R.S.
        Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009.
        Menopause. 2011; 18: 385-392
        • Manson J.E.
        • Chlebowski R.T.
        • Stefanick M.L.
        • et al.
        Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.
        JAMA. 2013; 310: 1353-1368
        • Rossouw J.E.
        • Prentice R.L.
        • Manson J.E.
        • et al.
        Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
        JAMA. 2007; 297: 1465-1477
        • Manson J.E.
        • Allison M.A.
        • Rossouw J.E.
        • et al.
        Estrogen therapy and coronary artery calcium.
        N Engl J Med. 2007; 356: 2591-2602
        • Chlebowski R.T.
        • Anderson G.L.
        • Gass M.
        • et al.
        Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
        JAMA. 2010; 304: 1684-1692
        • Anderson G.L.
        • Chlebowski R.T.
        • Rossouw J.E.
        • et al.
        Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
        Maturitas. 2006; 55: 103-115
        • Prentice R.L.
        • Manson J.E.
        • Langer R.D.
        • et al.
        Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
        Am J Epidemiol. 2009; 170: 12-23
        • Anderson G.L.
        • Chlebowski R.T.
        • Aragaki A.K.
        • et al.
        Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial.
        Lancet Oncol. 2012; 13: 476-486
        • Stuenkel C.A.
        • Gass M.L.
        • Manson J.E.
        • et al.
        A decade after the Women’s Health Initiative—the experts do agree.
        J Clin Endocrinol Metab. 2012; 97: 2617-2618
        • de Villiers T.J.
        • Gass M.L.S.
        • Haines C.J.
        • et al.
        Global consensus statement on menopausal hormone therapy.
        Maturitas. 2013; 74: 391-392
      3. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, in press.

      4. ACOG Practice Bulletin No. 141: management of menopausal symptoms.
        Obstet Gynecol. 2014; 123: 202-216
        • Reid R.
        • Abramson B.L.
        • Blake J.
        • et al.
        Managing menopause.
        J Obstet Gynaecol Can. 2014; 36: 830-833
        • North American Menopause Society
        The 2012 hormone therapy position statement of: the North American Menopause Society.
        Menopause. 2012; 19: 257-271
        • Goodman N.F.
        • Cobin R.H.
        • Ginzburg S.B.
        • et al.
        American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause.
        Endocr Pract. 2011; 17: 1-25
      5. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
        Menopause. 2013; 20: 888-902
        • Sturdee D.W.
        • Panay N.
        • on behalf of the International Menopause Society Writing Group
        Recommendations for the management of postmenopausal vaginal atrophy.
        Climacteric. 2010; 13: 509-522
        • Moyer V.A.
        • On behalf of the U.S. Preventive Services Task Force
        Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force Recommendation Statement.
        Ann Intern Med. 2013; 158: 47-54
        • Lobo R.A.
        • Davis S.R.
        • de Villiers T.J.
        • et al.
        Prevention of diseases after menopause.
        Climacteric. 2014; 17: 1-17
        • Deeks A.
        • Zoungas S.
        • Teede H.
        Risk perception in women: a focus on menopause.
        Menopause. 2008; 15: 304-309
        • Kenemans P.
        • van Unnik G.A.
        • Mijatovic V.
        • et al.
        Perspectives in hormone replacement therapy.
        Maturitas. 2001; 38: S41-S48
        • McBane S.E.
        • Borgelt L.M.
        • Barnes K.N.
        • et al.
        Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women’s Health Practice and Research Network of the American College of Clinical Pharmacy.
        Pharmacotherapy. 2014; 34: 410-423
        • Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee
        Committee opinion No. 532: compounded bioidentical menopausal hormone therapy.
        Obstet Gynecol. 2012; 120: 411-415
        • Goff D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • et al.
        2013 ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 129: S49-S57
        • Manson J.E.
        • Ames J.M.
        • Shapiro M.
        • et al.
        Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society.
        Menopause. 2015; 22: 247-253
        • Bushnell C.
        • McCullough L.D.
        • Awad I.A.
        • et al.
        Guidelines for the prevention of stroke in women. A statement for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2014; 45: 1545-1588
        • Amir E.
        • Freedman O.C.
        • Seruga B.
        • et al.
        Assessing women at high risk of breast cancer: a review of risk assessment models.
        J Natl Cancer Inst. 2010; 102: 680-691
        • Moyer V.A.
        • On behalf of the U.S. Preventive Services Task Force
        Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force Recommendation Statement.
        Ann Intern Med. 2013; 159: 698-708
        • Ursin G.
        • Ma H.
        • Wu A.H.
        • et al.
        Mammographic density and breast cancer in three ethnic groups.
        Cancer Epidemiol Biomarkers Prev. 2003; 12: 332-338
        • Kerlikowske K.
        • Cook A.J.
        • Buist D.S.
        • et al.
        Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
        J Clin Oncol. 2010; 28: 3830-3837
        • Hou N.
        • Hong S.
        • Wang W.
        • et al.
        Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.
        J Natl Cancer Inst. 2013; 105: 1365-1372
        • Visvanathan K.
        • Hurley P.
        • Banting E.
        • et al.
        Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline.
        J Clin Oncol. 2013; 31: 2942-2962
        • Utian W.H.
        • Shoupe D.
        • Bachmann G.
        • et al.
        Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
        Fertil Steril. 2001; 75: 1065-1079
        • Hedrick R.E.
        • Ackerman R.T.
        • Koltun W.D.
        • et al.
        Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
        Menopause. 2009; 16: 132-140
        • Grodstein F.
        • Manson J.E.
        • Stampfer M.J.
        • et al.
        Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy.
        Arch Intern Med. 2008; 168: 861-866
        • Shufelt C.L.
        • Merz C.N.
        • Prentice R.L.
        • et al.
        Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study.
        Menopause. 2014; 21: 260-266
        • Lokkegaard E.
        • Andreasen A.H.
        • Jacobsen R.K.
        • et al.
        Hormone therapy and risk of myocardial infarction: a national register study.
        Eur Heart J. 2008; 29: 2660-2668
        • Ettinger B.
        • Ensrud K.E.
        • Wallace R.
        • et al.
        Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.
        Obstet Gynecol. 2004; 104: 443-451
        • Schaefers M.
        • Muysers C.
        • Alexandersen P.
        • et al.
        Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
        Menopause. 2009; 16: 559-565
        • Bachmann G.A.
        • Schaefers M.
        • Uddin A.
        • et al.
        Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
        Obstet Gynecol. 2007; 110: 771-779
        • Huang A.
        • Yaffe K.
        • Vittinghoff E.
        • et al.
        The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women.
        Am J Obstet Gynecol. 2008; 198: 265.e1-265.e7
        • Bachmann G.A.
        • Schaefers M.
        • Uddin A.
        • et al.
        Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
        Menopause. 2009; 16: 877-882
        • Johnson S.R.
        • Ettinger B.
        • Macer J.L.
        • et al.
        Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
        Obstet Gynecol. 2005; 105: 779-787
        • Gupta P.
        • Ozel B.
        • Stanczyk F.
        • et al.
        The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
        Menopause. 2008; 15: 94-97
        • Grady D.
        • Vittinghoff E.
        • Lin F.
        • et al.
        Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
        Menopause. 2007; 14: 391-396
        • Renoux C.
        • Dell’aniello S.
        • Garbe E.
        • et al.
        Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
        BMJ. 2010; 340: c2519
        • Scarabin P.Y.
        Hormones and venous thromboembolism among postmenopausal women.
        Climacteric. 2014; 17: 34-37
        • American College of Obstetricians and Gynecologists
        ACOG committee opinion no. 556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism.
        Obstet Gynecol. 2013; 121: 887-890
        • Fournier J.P.
        • Duijnhoven R.G.
        • Renoux C.
        • et al.
        Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control study.
        Menopause. 2014; 21: 1023-1026
        • Fournier A.
        • Dossus L.
        • Mesrine S.
        • et al.
        Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008.
        Am J Epidemiol. 2014; 180: 508-517
        • Fournier A.
        • Mesrine S.
        • Dossus L.
        • et al.
        Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
        Breast Cancer Res Treat. 2014; 145: 535-543
        • Wildemeersch D.
        • Pylyser K.
        • DeWever N.
        • et al.
        Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.
        Maturitas. 2007; 57: 205-209
        • Orbo A.
        • Vereide A.
        • Arnes M.
        • et al.
        Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
        BJOG. 2014; 121: 477-486
        • Morelli M.
        • Di Cello A.
        • Venturella R.
        • et al.
        Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
        Gynecol Endocrinol. 2013; 29: 156-159
        • Soini T.
        • Hurskainen R.
        • Grenman S.
        • et al.
        Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.
        Obstet Gynecol. 2014; 124: 292-299
        • Mirkin S.
        • Pickar J.H.
        Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination.
        Int J Womens Health. 2013; 5: 465-475
        • Mirkin S.
        • Komm B.S.
        Tissue-selective estrogen complexes for postmenopausal women.
        Maturitas. 2013; 76: 213-220
        • Pinkerton J.V.
        • Harvey J.A.
        • Lindsay R.
        • et al.
        Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
        J Clin Endocrinol Metab. 2014; 99: E189-E198
        • Portman D.J.
        • Gass J.L.
        Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society.
        Menopause. 2014; 21: 1063-1068
        • Manson J.E.
        • Goldstein S.R.
        • Kagan R.
        • et al.
        Why the product labeling for low-dose vaginal estrogen should be changed.
        Menopause. 2014; 21: 911-916
        • Santen R.
        Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.
        Climacteric. 2015; 18: 121-134
        • Archer D.F.
        • Carr B.R.
        • Pinkerton J.V.
        • et al.
        Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.
        Menopause. 2014; ([Epub ahead of print])
        • Archer D.F.
        • Dorin M.
        • Lewis V.
        • et al.
        Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.
        Fertil Steril. 2001; 75: 1080-1087
        • Ockene J.K.
        • Barad D.H.
        • Cochrane B.B.
        • et al.
        Symptom experience after discontinuing use of estrogen plus progestin.
        JAMA. 2005; 294: 183-193
        • Arafah B.M.
        Increased need for thyroxine in women with hypothyroidism during estrogen therapy.
        N Engl J Med. 2001; 344: 1743-1749